S
SanegeneBio
Developing targeted RNAi-based medicines for obesity, cardiometabolic and autoimmune diseases
About SanegeneBio
SanegeneBio is an emerging biotechnology company specializing in RNA interference (RNAi) therapeutics. The company focuses on developing innovative RNAi-based drugs, particularly for chronic metabolic diseases. SanegeneBio operates in the biopharmaceutical market and serves clients in the healthcare and medical research sectors. The company employs a business model centered on research and development, clinical trials, and strategic collaborations. Revenue is generated through partnerships, licensing agreements, and the commercialization of its proprietary RNAi therapeutics. Notably, SanegeneBio has made significant strides in clinical development, with its first RNAi drug approved for clinical trials in China and ongoing Phase I trials in Australia. The company is headquartered in Suzhou and has recently moved into Phase III of BioBAY, a prominent biopharmaceutical hub. Key personnel include Dr. Jin Yuyan, who leads clinical and non-clinical development, bringing extensive experience from her tenure at Pfizer and Roche.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Woburn, United States
- Employees
- 32
- Open positions
- 3
- Dealroom signal
- 87.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Autoimmune, Metabolism, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2025 | $110M | $440M | Legend Capital · Oriza Holdings · Vivo Capital · TF Capital | ↗ |
| SERIES AOther financing | Dec 2023 | $80M | $500M | TF Capital · Yuansheng BioVenture · TEDA Venture Capital · Xiamen C&D Emerging Industry Equity Investment | ↗ |
Growth signals
Latest recorded traffic for SanegeneBio is 4.6K monthly website visits, up 84% over the last three months. SanegeneBio's team grew 33.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A21 investors entered at this stage
TF Capital
Yuansheng BioVenture- TCTEDA Venture Capital
Xiamen C&D Emerging Industry Equity Investment- LFLingang Blue Bay Fund
Tencent
Shenzhen Capital Group
Oriza Holdings
Qiming Venture Partners- K2K2VC
- ACAlwin Capital
SHC Shanghai Biomedical Fund- NCNorthern Lights Venture Capital
Legend Capital
Vivo Capital
NLVC
Invus
Eli Lilly
Sino Biopharmaceutical
Lake Bleu Capital
K2 Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SanegeneBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SanegeneBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.